Details of the Drug

General Information of Drug (ID: DM4DMBT)

• Drug Name: Chlorthalidone
• Synonyms: Chlorothalidone; Chlorphthalidolone; Chlorphthalidone; Chlortalidone; Chlortalidonum; Chlorthalidon; Clortalidona; Clortalidone; Famolin; Higroton; Hygroton; Igroton; Isoren; Natriuran; Oradil; Oxodolin; Oxodoline; Phthalamodine; Phthalamudine; Renon; Saluretin; Thalitone; Urolin; Zambesil; Clortalidone [DCIT]; Racemic chlorthalidone; G 33182; Chlortalidonum [INN-Latin]; Chlorthalidone (USP); Clortalidona [INN-Spanish]; G-33182; Hydro-Long; Hygroton (TN); Oksodolin (oxodolin); Thalitone (TN); Chlortalidone (JAN/INN); Chlorthalidone [USAN:INN:BAN]; (+-)-Chlorthalidone; (+-)-Hygroton; 1-Keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline; 1-Oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline; 2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide; 2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide; 3-(4'-Chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine; 3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine

Indication

Disease Entry	ICD 11	Status	REF
Edema	MG29	Approved	[1]
Hypertension	BA00-BA04	Approved	[1]
High blood pressure	BA00	Investigative	[2]

• Therapeutic Class: Antihypertensive Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 338.8
  Logarithm of the Partition Coefficient (xlogp); 0.9
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 1.5 mL/min/kg [4]
  Elimination: Approximately 50% of the administered dose is excreted unmetabolized through the kidney [5]
  Half-life: The concentration or amount of drug in body reduced by one-half in 40 - 50 hours []
  Metabolism: The drug is metabolized via the liver []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.45888 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.24% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.9 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.27 mg/mL [3]
• Chemical Identifiers:
  Formula: C14H11ClN2O4S
  IUPAC Name: 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide
  Canonical SMILES: C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O
  InChI: InChI=1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)
  InChIKey: JIVPVXMEBJLZRO-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2732
  ChEBI ID: CHEBI:3654
  CAS Number: 77-36-1
  DrugBank ID: DB00310
  TTD ID: D09NIA
  VARIDT ID: DR01029
  ACDINA ID: D00126
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Solute carrier family 12 member 1 (SLC12A1)	TTS087L	S12A1_HUMAN	Blocker	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Renin (REN)	OT52GZR2	RENI_HUMAN	Gene/Protein Processing	[8]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Chlorthalidone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Scopolamine	DMOM8AL	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Scopolamine.	Addictive disorder [6C50-6C5Z]	[9]
Dronedarone	DMA8FS5	Major	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Dronedarone.	Angina pectoris [BA40]	[10]
Promazine	DMZAL7W	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Promazine.	Appearance/behaviour symptom [MB23]	[11]
Rabeprazole	DMMZXIW	Moderate	Increased risk of hypomagnesemia by the combination of Chlorthalidone and Rabeprazole.	Bacterial infection [1A00-1C4Z]	[12]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Cariprazine.	Bipolar disorder [6A60]	[13]
Sotalol	DML60TN	Moderate	Increased risk of hyperglycemia by the combination of Chlorthalidone and Sotalol.	Cardiac arrhythmia [BC9Z]	[14]
Phenylbutazone	DMAYL0T	Moderate	Antagonize the effect of Chlorthalidone when combined with Phenylbutazone.	Chronic pain [MG30]	[15]
Ketoprofen	DMRKXPT	Moderate	Antagonize the effect of Chlorthalidone when combined with Ketoprofen.	Chronic pain [MG30]	[15]
Levomilnacipran	DMV26S8	Moderate	Increased risk of hyponatremia by the combination of Chlorthalidone and Levomilnacipran.	Chronic pain [MG30]	[16]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Chlorthalidone and Olopatadine.	Conjunctiva disorder [9A60]	[17]
Sertraline	DM0FB1J	Moderate	Increased risk of hyponatremia by the combination of Chlorthalidone and Sertraline.	Depression [6A70-6A7Z]	[16]
Fluoxetine	DM3PD2C	Moderate	Increased risk of hyponatremia by the combination of Chlorthalidone and Fluoxetine.	Depression [6A70-6A7Z]	[16]
Vilazodone	DM4LECQ	Moderate	Increased risk of hyponatremia by the combination of Chlorthalidone and Vilazodone.	Depression [6A70-6A7Z]	[16]
Paroxetine	DM5PVQE	Moderate	Increased risk of hyponatremia by the combination of Chlorthalidone and Paroxetine.	Depression [6A70-6A7Z]	[16]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Selegiline.	Depression [6A70-6A7Z]	[18]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hyponatremia by the combination of Chlorthalidone and Vortioxetine.	Depression [6A70-6A7Z]	[16]
Duloxetine	DM9BI7M	Moderate	Increased risk of hyponatremia by the combination of Chlorthalidone and Duloxetine.	Depression [6A70-6A7Z]	[16]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Isocarboxazid.	Depression [6A70-6A7Z]	[18]
Milnacipran	DMBFE74	Moderate	Increased risk of hyponatremia by the combination of Chlorthalidone and Milnacipran.	Depression [6A70-6A7Z]	[16]
Escitalopram	DMFK9HG	Moderate	Increased risk of hyponatremia by the combination of Chlorthalidone and Escitalopram.	Depression [6A70-6A7Z]	[16]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Tranylcypromine.	Depression [6A70-6A7Z]	[18]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of hyponatremia by the combination of Chlorthalidone and Desvenlafaxine.	Depression [6A70-6A7Z]	[16]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and OPC-34712.	Depression [6A70-6A7Z]	[13]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Phenelzine.	Depression [6A70-6A7Z]	[18]
Hyoscyamine	DM804UR	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Hyoscyamine.	Digestive system disease [DE2Z]	[9]
Mepenzolate	DM8YU2F	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Mepenzolate.	Digestive system disease [DE2Z]	[9]
Oxybutynine	DMJPBAX	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Oxybutynine.	Discovery agent [N.A.]	[9]
Trihexyphenidyl	DMB19L8	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Trihexyphenidyl.	Dystonic disorder [8A02]	[9]
Carbamazepine	DMZOLBI	Moderate	Increased risk of hyponatremia by the combination of Chlorthalidone and Carbamazepine.	Epilepsy/seizure [8A61-8A6Z]	[19]
Eslicarbazepine	DMZREFQ	Moderate	Increased risk of hyponatremia by the combination of Chlorthalidone and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[20]
Timolol	DM3NXRU	Moderate	Increased risk of hypertriglyceridemia by the combination of Chlorthalidone and Timolol.	Essential hypertension [BA00]	[14]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of fluid/electrolyte loss by the combination of Chlorthalidone and Ethacrynic acid.	Essential hypertension [BA00]	[21]
Nadolol	DMW6GVL	Moderate	Increased risk of hyperglycemia by the combination of Chlorthalidone and Nadolol.	Essential hypertension [BA00]	[14]
Mefenamic acid	DMK7HFI	Moderate	Antagonize the effect of Chlorthalidone when combined with Mefenamic acid.	Female pelvic pain [GA34]	[15]
Solifenacin	DMG592Q	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Solifenacin.	Functional bladder disorder [GC50]	[9]
Tolterodine	DMSHPW8	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Tolterodine.	Functional bladder disorder [GC50]	[9]
Darifenacin	DMWXLYZ	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Darifenacin.	Functional bladder disorder [GC50]	[9]
Propantheline	DM2EN6G	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Propantheline.	Gastric ulcer [DA60]	[9]
Dexlansoprazole	DM1DBV5	Moderate	Increased risk of hypomagnesemia by the combination of Chlorthalidone and Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[12]
Omeprazole	DM471KJ	Moderate	Increased risk of hypomagnesemia by the combination of Chlorthalidone and Omeprazole.	Gastro-oesophageal reflux disease [DA22]	[12]
Cisapride	DMY7PED	Major	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[22]
Acetazolamide	DM1AF5U	Minor	Interference of cell/tissue uptake of Chlorthalidone by Acetazolamide.	Glaucoma [9C61]	[23]
Methazolamide	DM7J2TA	Minor	Interference of cell/tissue uptake of Chlorthalidone by Methazolamide.	Glaucoma [9C61]	[23]
Carteolol	DMFMDOB	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Carteolol.	Glaucoma [9C61]	[14]
Dichlorphenamide	DMH7IDQ	Minor	Interference of cell/tissue uptake of Chlorthalidone by Dichlorphenamide.	Glaucoma [9C61]	[23]
Metipranolol	DMJMVKI	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Metipranolol.	Glaucoma [9C61]	[14]
Levobunolol	DMTNFCQ	Moderate	Increased risk of hyperglycemia by the combination of Chlorthalidone and Levobunolol.	Glaucoma [9C61]	[14]
Carvedilol	DMHTEAO	Moderate	Increased risk of hyperglycemia by the combination of Chlorthalidone and Carvedilol.	Heart failure [BD10-BD1Z]	[14]
Furosemide	DMMQ8ZG	Moderate	Increased risk of fluid/electrolyte loss by the combination of Chlorthalidone and Furosemide.	Heart failure [BD10-BD1Z]	[21]
Digoxin	DMQCTIH	Moderate	Increased risk of hypokalemia by the combination of Chlorthalidone and Digoxin.	Heart failure [BD10-BD1Z]	[24]
Bumetanide	DMRV7H0	Moderate	Increased risk of fluid/electrolyte loss by the combination of Chlorthalidone and Bumetanide.	Heart failure [BD10-BD1Z]	[21]
Digitoxin	DMWVIGP	Moderate	Increased risk of hypomagnesemia by the combination of Chlorthalidone and Digitoxin.	Heart failure [BD10-BD1Z]	[24]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Procarbazine.	Hodgkin lymphoma [2B30]	[18]
Acebutolol	DM0TI4U	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Acebutolol.	Hypertension [BA00-BA04]	[14]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Moexipril.	Hypertension [BA00-BA04]	[25]
Bisoprolol	DM3UZ95	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Bisoprolol.	Hypertension [BA00-BA04]	[14]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Captopril.	Hypertension [BA00-BA04]	[25]
Trandolapril	DM4L6EU	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Trandolapril.	Hypertension [BA00-BA04]	[25]
Nebivolol	DM7F1PA	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Nebivolol.	Hypertension [BA00-BA04]	[14]
Fosinopril	DM9NJ52	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Fosinopril.	Hypertension [BA00-BA04]	[25]
Pindolol	DMD2NV7	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Pindolol.	Hypertension [BA00-BA04]	[14]
Benazepril	DMH1M9B	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Benazepril.	Hypertension [BA00-BA04]	[25]
Labetalol	DMK8U72	Moderate	Increased risk of hypertriglyceridemia by the combination of Chlorthalidone and Labetalol.	Hypertension [BA00-BA04]	[14]
Enalapril	DMNFUZR	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Enalapril.	Hypertension [BA00-BA04]	[25]
Atenolol	DMNKG1Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Atenolol.	Hypertension [BA00-BA04]	[14]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Perindopril.	Hypertension [BA00-BA04]	[25]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Quinapril.	Hypertension [BA00-BA04]	[25]
Lisinopril	DMUOK4C	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Lisinopril.	Hypertension [BA00-BA04]	[25]
Belladonna	DM2RBWK	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Belladonna.	Infectious gastroenteritis/colitis [1A40]	[9]
Meclofenamic acid	DM05FXR	Moderate	Antagonize the effect of Chlorthalidone when combined with Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[15]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Propiomazine.	Insomnia [7A00-7A0Z]	[13]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and ITI-007.	Insomnia [7A00-7A0Z]	[13]
Clidinium	DMUMQZ0	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Clidinium.	Irritable bowel syndrome [DD91]	[9]
Dicyclomine	DMZSDGX	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Dicyclomine.	Irritable bowel syndrome [DD91]	[9]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Chlorthalidone and Porfimer Sodium.	Lung cancer [2C25]	[26]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[27]
Propranolol	DM79NTF	Moderate	Increased risk of hyperglycemia by the combination of Chlorthalidone and Propranolol.	Migraine [8A80]	[14]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Ozanimod.	Multiple sclerosis [8A40]	[18]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Chlorthalidone and Methoxsalen.	Mycosis fungoides [2B01]	[11]
Droperidol	DM0DXA8	Major	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Droperidol.	Nausea/vomiting [MD90]	[28]
Prochlorperazine	DM53SRA	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Prochlorperazine.	Nausea/vomiting [MD90]	[11]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Promethazine.	Nausea/vomiting [MD90]	[13]
Thiethylperazine	DMU3IET	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Thiethylperazine.	Nausea/vomiting [MD90]	[13]
Sibutramine	DMFJTDI	Moderate	Increased risk of hyponatremia by the combination of Chlorthalidone and Sibutramine.	Obesity [5B80-5B81]	[16]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Levomethadyl Acetate.	Opioid use disorder [6C43]	[29]
Rofecoxib	DM3P5DA	Moderate	Antagonize the effect of Chlorthalidone when combined with Rofecoxib.	Osteoarthritis [FA00-FA05]	[15]
Valdecoxib	DMAY7H4	Moderate	Antagonize the effect of Chlorthalidone when combined with Valdecoxib.	Osteoarthritis [FA00-FA05]	[15]
Diclofenac	DMPIHLS	Moderate	Antagonize the effect of Chlorthalidone when combined with Diclofenac.	Osteoarthritis [FA00-FA05]	[15]
Naproxen	DMZ5RGV	Moderate	Antagonize the effect of Chlorthalidone when combined with Naproxen.	Osteoarthritis [FA00-FA05]	[15]
Diflunisal	DM7EN8I	Moderate	Antagonize the effect of Chlorthalidone when combined with Diflunisal.	Pain [MG30-MG3Z]	[15]
Ibuprofen	DM8VCBE	Moderate	Antagonize the effect of Chlorthalidone when combined with Ibuprofen.	Pain [MG30-MG3Z]	[15]
Nabumetone	DMAT2XH	Moderate	Antagonize the effect of Chlorthalidone when combined with Nabumetone.	Pain [MG30-MG3Z]	[15]
Flavoxate	DMKV4NL	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Flavoxate.	Pain [MG30-MG3Z]	[9]
Piroxicam	DMTK234	Moderate	Antagonize the effect of Chlorthalidone when combined with Piroxicam.	Pain [MG30-MG3Z]	[15]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Safinamide.	Parkinsonism [8A00]	[18]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Rasagiline.	Parkinsonism [8A00]	[18]
Biperiden	DME78OA	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Biperiden.	Parkinsonism [8A00]	[9]
Procyclidine	DMHFJDT	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Procyclidine.	Parkinsonism [8A00]	[9]
Methylscopolamine	DM5VWOB	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Methylscopolamine.	Peptic ulcer [DA61]	[9]
Esomeprazole	DM7BN0X	Moderate	Increased risk of hypomagnesemia by the combination of Chlorthalidone and Esomeprazole.	Peptic ulcer [DA61]	[12]
Ketorolac	DMI4EL5	Moderate	Antagonize the effect of Chlorthalidone when combined with Ketorolac.	Postoperative inflammation [1A00-CA43]	[15]
Bromfenac	DMKB79O	Moderate	Antagonize the effect of Chlorthalidone when combined with Bromfenac.	Postoperative inflammation [1A00-CA43]	[15]
Verteporfin	DMIY6DB	Moderate	Increased risk of photosensitivity reactions by the combination of Chlorthalidone and Verteporfin.	Psoriasis [EA90]	[30]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Levomepromazine.	Psychotic disorder [6A20-6A25]	[13]
Fluphenazine	DMIT8LX	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Fluphenazine.	Psychotic disorder [6A20-6A25]	[11]
Triflupromazine	DMKFQJP	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Triflupromazine.	Psychotic disorder [6A20-6A25]	[11]
Meloxicam	DM2AR7L	Moderate	Antagonize the effect of Chlorthalidone when combined with Meloxicam.	Rheumatoid arthritis [FA20]	[15]
Sulindac	DM2QHZU	Moderate	Antagonize the effect of Chlorthalidone when combined with Sulindac.	Rheumatoid arthritis [FA20]	[15]
Celecoxib	DM6LOQU	Moderate	Antagonize the effect of Chlorthalidone when combined with Celecoxib.	Rheumatoid arthritis [FA20]	[15]
Oxaprozin	DM9UB0P	Moderate	Antagonize the effect of Chlorthalidone when combined with Oxaprozin.	Rheumatoid arthritis [FA20]	[15]
Flurbiprofen	DMGN4BY	Moderate	Antagonize the effect of Chlorthalidone when combined with Flurbiprofen.	Rheumatoid arthritis [FA20]	[15]
Fenoprofen	DML5VQ0	Moderate	Antagonize the effect of Chlorthalidone when combined with Fenoprofen.	Rheumatoid arthritis [FA20]	[15]
Indomethacin	DMSC4A7	Moderate	Antagonize the effect of Chlorthalidone when combined with Indomethacin.	Rheumatoid arthritis [FA20]	[15]
Tolmetin	DMWUIJE	Moderate	Antagonize the effect of Chlorthalidone when combined with Tolmetin.	Rheumatoid arthritis [FA20]	[15]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Quetiapine.	Schizophrenia [6A20]	[13]
Mesoridazine	DM2ZGAN	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Mesoridazine.	Schizophrenia [6A20]	[11]
Thioridazine	DM35M8J	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Thioridazine.	Schizophrenia [6A20]	[11]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Aripiprazole.	Schizophrenia [6A20]	[13]
Iloperidone	DM6AUFY	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Iloperidone.	Schizophrenia [6A20]	[11]
Paliperidone	DM7NPJS	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Paliperidone.	Schizophrenia [6A20]	[11]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Loxapine.	Schizophrenia [6A20]	[13]
Haloperidol	DM96SE0	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Haloperidol.	Schizophrenia [6A20]	[11]
Perphenazine	DMA4MRX	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Perphenazine.	Schizophrenia [6A20]	[11]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Molindone.	Schizophrenia [6A20]	[13]
Chlorpromazine	DMBGZI3	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Chlorpromazine.	Schizophrenia [6A20]	[11]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Thiothixene.	Schizophrenia [6A20]	[13]
Clozapine	DMFC71L	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Clozapine.	Schizophrenia [6A20]	[13]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Trifluoperazine.	Schizophrenia [6A20]	[11]
Risperidone	DMN6DXL	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Risperidone.	Schizophrenia [6A20]	[11]
Olanzapine	DMPFN6Y	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Olanzapine.	Schizophrenia [6A20]	[13]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Amisulpride.	Schizophrenia [6A20]	[11]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Asenapine.	Schizophrenia [6A20]	[13]
Pimozide	DMW83TP	Major	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Pimozide.	Schizophrenia [6A20]	[31]
Atropine	DMEN6X7	Minor	Altered absorption of Chlorthalidone due to GI dynamics variation caused by Atropine.	Unspecific substance harmful effect [NE6Z]	[9]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[13]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Chlorthalidone and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[32]
Amiodarone	DMUTEX3	Major	Increased risk of ventricular arrhythmias by the combination of Chlorthalidone and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[33]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 1	E00263	19700	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate	E00244	15324	lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Chlorthalidone 50 mg tablet	50 mg	Oral Tablet	Oral
Chlorthalidone 25 mg tablet	25 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7147).
• [2] Chlorthalidone FDA Label
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Kountz DS, Goldman A, Mikhail J, Ezer M: Chlorthalidone: the forgotten diuretic. Postgrad Med. 2012 Jan;124(1):60-6. doi: 10.3810/pgm.2012.01.2518.
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52.
• [8] Detection of low-renin hypertension; evaluation of out-patient renin-stimulating methods. Clin Sci Mol Med. 1975 Feb;48(2):91-6. doi: 10.1042/cs0480091.
• [9] Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
• [10] Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
• [11] Cerner Multum, Inc. "Australian Product Information.".
• [12] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
• [13] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [14] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
• [15] Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
• [16] Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
• [17] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [18] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [19] Yassa R, Nastase C, Camille Y, Henderson M, Belzile L, Beland F "Carbamazepine, diuretics, and hyponatremia: a possible interaction." J Clin Psychiatry 48 (1987): 281-3. [PMID: 3597330]
• [20] Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
• [21] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61. [PMID: 6701709]
• [22] Product Information. Propulsid (cisapride). Janssen Pharmaceutica, Titusville, NJ.
• [23] Beermann B, Hellstrom K, Lindstrom B, Rosen A "Binding-site interaction of chlorthalidone and acetazolamide, two drugs transported by red blood cells." Clin Pharmacol Ther 17 (1975): 424-32. [PMID: 804371]
• [24] Brown DD, Dormois JC, Abraham GN, et al "Effect of furosemide on the renal excretion of digoxin." Clin Pharmacol Ther 20 (1976): 395-400. [PMID: 975715]
• [25] Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
• [26] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [27] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [28] Canadian Pharmacists Association.
• [29] Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
• [30] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [31] Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
• [32] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [33] Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]